RhPDCD5 combined with dexamethasone increases antitumor activity in multiple myeloma partially via inhibiting the Wnt signalling pathway
- 9 November 2017
- journal article
- research article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 45 (2) , 140-145
Abstract
Summary: Multiple myeloma (MM) is one of the most common hematological malignancies and characterized by the clonal accumulation of malignant plasma cells. Significant progress has been made in MM treatment recently, while MM still remains incurable. Our previous studies showed that the recombined human programmed cell death 5 (rhPDCD5) can promote MM apoptosis induced by dexamethasone (Dex). Here, we expanded the findings by showing that the rhPDCD5 alone could not induce an obvious growth inhibition of U266 cells (a MM cell line). Of note, with the combination of dexamethasone (Dex), the growth of MM cells was significantly inhibited and accompanied with the cell cycle arrest in G0/G1. For mechanism study, we found that the combination treatment of rhPDCD5 plus Dex downregulated the mRNA and protein expressions of Wnt effectors including β‐catenin, β‐catenin (Ser675), TCF4, survivin and c‐Myc when compared to Dex only. Moreover, the activation of WNT pathway induced by LiCl can also be inhibited by this combination treatment. Taken together, our study demonstrated that the combination of rhPDCD5 and Dex can suppress the proliferation of multiple myeloma cells partially via inhibiting the WNT signalling pathway.Keywords
Funding Information
- National Natural Science Foundation of China (81470361, 81670203)
- China Scholarship Council (201706370184)
This publication has 24 references indexed in Scilit:
- PDCD5 expression predicts a favorable outcome in patients with hepatocellular carcinomaInternational Journal of Oncology, 2013
- Multiple myeloma: the disease and its treatmentInternational Journal of Basic & Clinical Pharmacology, 2013
- Wnt Inhibitor Screen Reveals Iron Dependence of β-Catenin Signaling in CancersCancer Research, 2011
- Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomasOncology Reports, 2011
- Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivoApoptosis, 2010
- Characterization of Wnt/β‐catenin signalling in osteoclasts in multiple myelomaBritish Journal of Haematology, 2010
- Ethacrynic Acid Exhibits Selective Toxicity to Chronic Lymphocytic Leukemia Cells by Inhibition of the Wnt/β-Catenin PathwayPLOS ONE, 2009
- Is NF-κB a good target for cancer therapy? Hopes and pitfallsNature Reviews Drug Discovery, 2009
- SnapShot: Wnt/β-Catenin SignalingCell, 2007
- TFAR19,a Novel Apoptosis-Related Gene Cloned from Human Leukemia Cell Line TF-1, Could Enhance Apoptosis of Some Tumor Cells Induced by Growth Factor WithdrawalBiochemical and Biophysical Research Communications, 1999